Wockhardt Share Price on NSE India Today: A Comprehensive Overview
Wockhardt Limited, a prominent player in India's pharmaceutical and biotechnology sector, has witnessed significant fluctuations in its share price on the National Stock Exchange (NSE) of India. As of June 11, 2025, the stock is trading at ₹1,470.25, reflecting a gain of 3.40% from the previous close .
Wockhardt Share Price Snapshot
| Metric | Value |
|---|---|
| Current Price | ₹1,470.25 |
| Today's Change | +₹48.30 (+3.40%) |
| 52-Week Low | ₹490.15 |
| 52-Week High | ₹1,679.90 |
| Market Cap | ₹23,889 Cr |
| P/E Ratio (TTM) | -51.60 |
| EPS (TTM) | -₹28.49 |
| Book Value per Share | ₹218.97 |
| Debt to Equity Ratio | 0.63 |
| Dividend Yield | 0% |
Financial Highlights
-
Market Capitalization: ₹23,889 Crore
-
Price-to-Book (P/B) Ratio: 6.71
-
Return on Equity (ROE): -14.10%
-
Return on Capital Employed (ROCE): -1.89%
-
Earnings Per Share (EPS): -₹28.49
-
Debt-to-Equity Ratio: 0.63
These figures indicate that while Wockhardt's stock has shown substantial growth, the company is currently operating at a loss, as reflected in its negative EPS and ROE.
Recent Performance and Trends
Over the past year, Wockhardt's stock has experienced notable volatility:
-
1-Year Return: +130.99%
-
3-Year Return: +386.26%
-
5-Year Return: +392.76%
Despite recent gains, the stock has faced challenges, including a decline of 19.21% over the past three months .
Developments Influencing Share Price
Several factors have contributed to the fluctuations in Wockhardt's share price:
1. Zaynich's Clinical Trials
Wockhardt's experimental antibiotic, Zaynich, has shown promising results in Phase III clinical trials, demonstrating up to 96.8% efficacy against multidrug-resistant bacteria. This has generated significant investor interest and positively impacted the stock price .
2. Regulatory Approvals
The company's receipt of approval from the Central Drugs Standard Control Organization (CDSCO) for a new pneumonia drug has bolstered investor confidence, leading to a 5% increase in the stock price .
3. Market Dynamics
Global market conditions, including potential pharmaceutical tariffs and competition from other pharmaceutical companies, have introduced volatility, affecting Wockhardt's stock performance .
Peer Comparison
| Company Name | 1-Year Return (%) | P/E Ratio (TTM) | P/B Ratio |
|---|---|---|---|
| Wockhardt Ltd | 130.99 | -51.60 | 6.71 |
| Sun Pharmaceutical | 16.82 | 43.84 | 5.12 |
| Divi's Laboratories | 58.94 | 33.67 | 4.76 |
| Cipla Ltd | 8.68 | 28.27 | 5.04 |
| Torrent Pharma | 24.12 | 20.87 | 4.84 |
Investment Considerations
Investors should consider the following factors before investing in Wockhardt:
-
Clinical Trial Outcomes: The success of Zaynich's Phase III trials will be crucial in determining future stock performance.
-
Regulatory Approvals: Timely approvals for new drugs can positively impact the stock.
-
Market Conditions: Global pharmaceutical policies and competition can influence stock volatility.
Conclusion
Wockhardt Ltd's share price on the NSE reflects a blend of promising developments and ongoing challenges. While the company has shown significant growth over the past year, investors should remain cautious and stay informed about clinical trial results and regulatory developments.
For real-time updates and detailed financial analysis, investors are encouraged to consult reliable financial platforms and consider seeking advice from financial advisors.
